Summit Therapeutics

Summit Therapeutics is a biopharmaceutical company that discovers, develops, and commercializes patient-, physician-, caregiver-, and societal-friendly medical innovations for serious unmet medical needs. Its lead candidate is ivonescimab (SMT112), a PD-1/VEGF bispecific antibody licensed from Akeso, which is being developed mainly for non-small cell lung cancer and other solid tumors.